Summary
The Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis trial [ASCEND; King TE et al. N Engl J Med 2014] was a Phase 3, multinational, double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. This trial discusses findings.
- Pulmonary Clinical Trials
- Lower Respiratory Infections
- Pulmonary Clinical Trials
- Pulmonary & Critical Care
- Lower Respiratory Infections
- © 2014 MD Conference Express®
Tools
Table of contents
Cited By...
- No citing articles found.